Rather unsurprising finding at this point, but valuable nonetheless Per usual, joint efficacy for bimekizumab (IL17i) ~similar to TNF New twist; similar loss in efficacy over time. Nice to have another IL17i; not sure this is a "blockbuster" @RheumNow #ACR23 Abstr1437 https://t.co/4sVfSz7ZnK

In axSpA, the mean and median progression were 0.54 and 0.38 points in mSASSS per year respectively, lower than what has been reported in similar cohorts, LBP before diagnosis was a strong predictor of progression, Granados R Abst#1389 #ACR23 @RheumNow https://t.co/fvkOzhUG97 https://t.co/k18HxWswbs

Great Debate on the use of biologics in treatment of Giant Cell Arteritis and Polymyalgia Rheumatica! Let's begin with Dr. Robert Spiera on why we should NOT use IL-6i No evidence of disease modifying Lose biomarker activity Cost @RheumNow #ACR23 #ACRbest https://t.co/XCT02wYb2s

Interesting abstract re:dx trajectories, I have a counter-intuitive take I expect pts w/high dx activity to respond BETTER than pts w/LDA at diagnosis More autoimmunity + less fibro = higher chance to respond to DMARD? Anyone else feel that way? @RheumNow #ACR23 Abstr1426 https://t.co/D6GU7tMcY6

How does Dr. Robert Spiera manage GCA? 1) Tx with steroids alone, taper by 6 months 2) Do not chase ESR/CRP 3) Pay attention to steroid complications 4) Low threshold to use IL-6i Similar plan for PMR Taper steroids by month 4 @RheumNow #ACR23 https://t.co/KSwyfjobFY

Here is the popular answer@to the #ACR23 debate of up front bDMARD in GCA and PMR Yes vs No. the audience has no consensus. Access is Impt, experience and criteria of who to use it in. ⁦@ACRheum⁩ ⁦@RheumNow⁩ https://t.co/7pxF4w926m

@philseo on why we SHOULD use IL-6i in GCA and PMR 1) Infection risk similar to TNFi 2) Too many (63%) pts remain on steroids at 1-2 yrs 3) May accelerate remission 4) Steroids are Bad, even at low doses @RheumNow #ACR23 https://t.co/muPPcAc6LC

Still uncomfortable with IL-6i in GCA or PMR especially given the pt population and potential AE? Be on the look out for NEW biologics! Mavrilimumab Secukinumab and MORE! @RheumNow #ACR23 https://t.co/gdcDIcvffa

More vitamin D during pregnancy is better, right? Hopkins Lupus cohort, vit D levels & adverse pregnancy outcomes Actually, there's a sweet spot (too high just as unfavourable as too low) Maybe popping vit D pills isn't always limitless @jhrheumatology #ACR23 ABST1364 @RheumNow https://t.co/TVPCqP3dq9

Patients with autoimmnue diseases have a high maternal and fetal complication rate! Abst 1003 #ACR23 @RheumNow https://t.co/pnvvBUN2JG